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Chlormadinone acetate is effective for hot flush during 
androgen deprivation therapy
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Purpose: To investigate the clinical efficacy of low-dose chlormadinone acetate (CMA) in prostate cancer patients who suffer from 
hot flushes that is a major side effect of androgen deprivation therapy.
Methods: Our study included 32 prostate cancer patients who had severe hot flush after undergoing hormone therapy for more 
than 3 months. The average age of the patients was 72.5 years. In the beginning, patients received CMA at 100 mg orally per day. We 
defined the hot flush as disappeared, improved, or not improved. In patients with disappeared or improved symptoms, we decreased 
CMA dose to 50 mg per day, and after we reevaluated the effect, we decreased CMA dose to 25 mg per day. When hot flush appeared 
again at 25 mg per day, we returned the dose of CMA to 50 mg per day. In cases with no change for more than two months, we canceled 
the treatment of CMA.
Results: Hot flush disappeared in 17 patients, improved in 10 patients, and did not improve in 5 patients (reduction in 84% of hot 
flush patients). The median time to hot flush reduction was 1.16 months. The effect of CMA was maintained at 25 mg per day in 19 
patients and at 50 mg per day in 8 patients. No patients had prostate-specific antigen failure in the treatment of CMA.
Conclusions: When hot flush appears during treatment with luteinizing hormone-releasing hormone agonist for prostate cancer, it 
seems that CMA can improve it immediately in most patients.
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INTRODUCTION
Hot flush is a major side effect of androgen deprivation therapy 
for prostate cancer patients. Up to 80% of patients undergoing 
treatment with gonadotropin-releasing hormone (GnRH) an-
alogues report hot flushes, and up to 27% report hot flushes 
as being the most troublesome side effect of treatment [1]. 
Although the pathophysiology of hot flush is incompletely 
understood, a number of effective therapies are available for 
its management. For example, there are transdermal estrogen 
patch [2] and megestrol acetate [3] amongst hormonal treat-
ment options, and clonidine [4], gabapentin [5], and selective 
serotonin reuptake inhibitor (SSRI) [6] amongst nonhormon-
al treatment options.
 Chlormadinone acetate (CMA) is a steroidal antiandrogen 
similar to progesterone used in maximum androgen block-
ade (MAB) therapy as well as monotherapy for prostate can-
cer in Japan. We investigated the clinical efficacy of low-dose 
CMA in prostate cancer patients who suffer from hot flushes.
MATERIALS AND METHODS
Our study included 32 prostate cancer patients who had se-
vere hot flush after undergoing hormone therapy for more 
Koike, et al. CMA is effective for hot flush
114
PROSTATE INTERNATIONAL
http://dx.doi.org/10.12954/PI.12010
than 3 months (Table 1). In 30 patients who had been treated 
with only luteinizing hormone-releasing hormone (LH-RH), 
CMA was administered. In 2 patients who had been treated 
with MAB using bicalutamide (and whose cancer control was 
good), bicalutamide was changed to CMA. The average age 
of the patients was 72.5 years. The mean of prostate-specific 
antigen (PSA) before LH-RH agonist treatment was 35.2 ng/mL. 
Clinical stages of the enrolled patients were T1–T2N0M0 in 
24, T3N0M0 in 6, N1M0 in one, and M1 in one, respectively. 
The median time to hot flush appearing after initiating hor-
mone therapy was 5.5 months. In the beginning, patients 
received CMA at 100 mg orally per day. One doctor evaluated 
the curative effect four weeks later. We defined the evaluation 
of hot flush as disappeared (the symptom disappeared when 
conscious), improved (the symptom improve when con-
scious), not improved (the symptom did not improve when 
conscious). In patients with disappeared or improved symp-
toms, we decreased CMA dose to 50 mg per day. Four weeks 
later, we reevaluated the effect, and we decreased CMA dose 
to 25 mg per day. When hot flush appeared again at 25 mg per 
day, we returned the dose of CMA to 50 mg per day. Basically, 
CMA treatmet was continued as long as it was effective. In 
cases with no change for more than two months, we canceled 
the treatment of CMA. This study was approved by the Ethical 
Committee of Gunma University Hospital.
RESULTS
Hot flush disappeared in 17 patients, was improved in 10 pa-
tients, was not improved in 5 patients (reduction in 84% of hot 
flush patients). The median time to hot flush reduction was 1.16 
months. The effect of CMA was maintained at 25 mg per day in 
19 patients and at 50 mg per day in 8 patients (Fig. 1). The role 
of ADT in the patients enrolled in this study and average du-
ration of CMA in patients with response of CMA were shown 
in Table 2. No patients had PSA failure in the treatment of 
CMA. Adverse events were mild as shown in Table 3. 
DISCUSSION
A number of effective therapies are available for the man-
agement of hot flush [7]. Recently, Suzuki et al. [8] reported 
the clinical efficacy of milnacipran, serotonin-noradrenalin 
reuptake inhibitor (SNRI) in prostate cancer patients who 
suffer from hot flushes. It is reported that SNRI has a stronger 
effect for depression and less side effects in comparison with 
SSRI [9]. Their study included 12 patients who had taken hor-
Table 1. The characterisitics of the enrolled patients
Characterisitic Value
Age (yr), average (range) 72.5 (59–85)
Serum PSA (ng/mL)
<10 14
10–20 10
>20 8
Testosterone (ng/mL), average (range) 4.16 (2.1–8.7)
Clinical stage
T1–T2N0M0 24
T3N0M0 6
N1M0 1
M1 1
Gleason score
6 3
7 20
8 2
9 7
Purpose of use of LH-RHa
Monotherapy 15
Combination with radiation 15
Salvage 2
PSA, prostate-specific antigen; LH-RHa, luteinizing hormone-releasing 
hormone agonist.
Table 2. The average duration of the chlormadinone acetate 
(CMA) treatment in responsive case
CMA treatment Duration (mo), average (range)
Monotherapy 26.8 (5–78)
Combination with radiation 16.4 (3–76)
Salvage 14.2 (4–24)
Table 3. The adverse events of chlormadinone acetate treat-
ment
No. (%) Grade
Hyperhidrosis 1 (3.1) 2
ALT, AST increased 1 (3.1) 2
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Patients Disappeared Improved Not improved
Disappeared 
+ Improved
32 17 10 5 84%
The average time to hot flush reduction : 1.16 months
[the progress of the patients with CMA]
CMA (mg/day) 100 mg 25 mg50 mg
50 mg
8
192727Patients
Fig. 1. The effect of chlormadine acetate (CMA).
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mone therapy for at least 3 months prior to the trial entry. At 
12 weeks, 9 patients were available for the evaluation. Four 
patients received 50 mg per day and 5 patients received 25 
mg per day. The patients with ≥ 50% decrease in baseline hot 
flash score were observed in 3 out of 4 who received 50 mg 
and 2 out of 5 who received 25 mg per day. The frequency of 
hot flushes had significantly decreased at the 12 weeks period 
than the baseline in the milnacipran 50 mg per day treatment 
group. These results indicated that milnacipran 50 mg per day 
therapy is effective in the treatment of hot flushes.
 A previous study showed that the effect was comparatively 
high with corpus luteum hormone drug [10]. Irani et al. [11] 
reported a multicenter, randomized, double-blind study to 
compare the efficacy of venlafaxine, cyproterone acetate, and 
medroxyprogesterone acetate for the treatment of hot flushes 
in patients with prostate cancer who were being treated 
with GnRH analogues. They concluded after 6 months of 
treatment that leuprorelin, venlafaxine, cyproterone, and 
medroxyprogesterone were effective in reducing hot flushes. 
However, the hormonal treatments cyproterone and me-
droxyprogesterone were significantly more effective than ven-
lafaxine. As cyproterone is a recognised treatment in prostate 
cancer, and its use could interfere with hormonal therapy, 
medroxyprogesterone could be considered to be the standard 
treatment for hot flushes in men undergoing androgen sup-
pression for prostate cancer. In Japan, Sakai et al. [12] under-
took a prospective, randomized study to longitudinally exam-
ine the status of the development of hot flushes in, and quality 
of life of, Japanese patients with prostate cancer who under-
went combined androgen blockade (CAB) with a steroidal or 
nonsteroidal antiandrogen. They reported that the median 
frequencies of hot flushes daily were 1.3 and 2.2 for warmth/
flushing (P = 0.16) and 1.0 and 3.6 for sweating (P = 0.021) in 
the chlormadinone and bicalutamide groups, respectively. 
Patients in the chlormadinone group were significantly less 
likely to be distressed by warmth/flushing (odds ratio, 0.47; 
P < 0.001) and sweating (odds ratio, 0.61; P = 0.01) than those 
in the bicalutamide group. They concluded that CAB using a 
steroidal antiandrogen such as chlormadinone might induce 
fewer and less-distressing hot flushes than CAB with bicalu-
tamide. These finding prompted us to use CMA for prostate 
cancer patients who had severe hot flush in during treatment 
with GnRH analogues. In this study, reduction in 84% of hot 
flush patients was observed. There are not many reports in 
which CMA was used for hot flush during treatment with 
GnRH analogue. Suzuki et al. [13,14] evaluated the incidence 
of hot flushes in sixty-eight prostate cancer patients receiving 
endocrine therapy. The overall incidence of hot flushes was 
37%, and hot flushes improved after 4 weeks in 3 of 4 patients 
(75%) treated by CMA. They used CMA again for ten hot flush 
patients later. Hot flushes improved after 4 weeks in 9 of 10 
patients (90%).
 With regard to problems concerning the CMA dosage, using 
steroidal anti androgen in MAB treatment has been identi-
fied as disadvantageous by meta-analysis [15,16]. The results 
for cyproterone acetate, which accounted for only a fifth of 
the evidence, appeared slightly unfavorable to MAB (5-year 
survival, 15.4% with MAB vs. 18.1% with androgen suppres-
sion [AS] alone; difference, –2.8% [standard error {SE}, 2.4]; 
log-rank, P = 0.04 adverse), whereas those for nilutamide and 
flutamide appeared slightly favorable (5-year survival, 27.6% 
with MAB vs. 24.7% with AS alone; difference, 2.9% [SE, 1.3]; 
log-rank, P = 0.005) [15]. Sakai et al. [12] stated that, from the 
viewpoint of safety, chlormadinone, not cyproterone, was 
developed as a therapeutic drug for prostate cancer in Japan, 
but because their study had a limited duration of 2 years, the 
difference in survival time between the treatment groups 
was not assessed. Against such a background, we carried out 
gradual decrease of dose of CMA to avoid disadvantageous 
effects for prostate cancer treatment. Although the usual dose 
of CMA for prostate cancer is 100 mg/day, hot flush disap-
peared in all patients at 50 mg/day. Furthermore, the effect of 
CMA was maintained at 25 mg/day in many patients. In ad-
dition, no patients had PSA failure in the treatment of CMA. 
Considering the above, the gradual decrease of dose of CMA 
may be appropriate for treating hot flush.
 The limitation of this study is the relative small number of 
enrolled patients, and the one-armed observation study. We 
are planning to add the number of patients, and to reevaluate 
the efficacy of CMA.
 In conclusion, when hot flush appears during treatment 
with LH-RH agonist for prostate cancer, CMA might improve 
hot flush. If the effect of CMA is maintained, low dose CMA 
might be used. 
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